# InfuSystems Holdings Inc. (INFU) fundamentals

Data as of 2026-11-11. AMEX, United States. Sector: Healthcare / Medical Devices & Supplies. Price $15.28, market value $306 million.

## Valuation
- **P/E (trailing): 34.7×** (5-yr avg 163.3×, 3-yr avg 123.1×). InfuSystems Holdings Inc. trades at 34.7× trailing earnings, well below its own five-year average of 163.3×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 27.3×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.15**. A PEG of 0.15 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 2.1×**. Each dollar of revenue is priced at 2.1×.
- **Price / book: 4.8×**. The shares trade at 4.8× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 12.2×**. Enterprise value is 12.2× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 7.5%** (5-yr avg 8.2%). Free cash flow equals 7.5% of the market value, in line with its five-year average of 8.2%. Above 5% is generally attractive.
- **Earnings yield: 2.9%**. The inverse of the P/E: 2.9% of the price is earned each year.

## Profitability
- **Gross margin: 57.5%**. InfuSystems Holdings Inc. keeps 57.5% of revenue after the direct cost of what it sells.
- **Operating margin: 9.3%**. 9.3% of revenue is left after running the business.
- **Net margin: 4.6%**. 4.6% of each dollar of sales reaches the bottom line.
- **Return on equity: 11.6%**. 11.6% on shareholders' equity is solid.
- **Return on invested capital: 14.2%**. Return on all capital, debt included, is 14.2%.
- **Return on assets: 8.5%**. Each dollar of assets produces 8.5% of profit.

## Growth
- **Revenue growth (1 yr): 6.4%** (3-yr 9.3%/yr, 5-yr 8.1%/yr). Revenue grew 6.4% over the last year, against 8.1% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 181.8%** (5-yr -17.3%/yr). Earnings per share rose 181.8%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): 13.0%/yr**. Free cash flow has compounded at 13.0% a year over three years.

## Financial health
- **Debt to equity: 0.34**. Debt is 0.34 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 0.6×**. It would take 0.6 years of operating earnings to repay net borrowings, within the comfortable range.
- **Current ratio: 1.80** (quick 1.80). Current assets cover the next year's liabilities 1.80 times.
- **Altman Z-score: 7.06**. A Z-score of 7.06 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 8/9**. 8 of 9 fundamental checks pass: strong and improving financials.

## Dividends
- **Dividend: none**. InfuSystems Holdings Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 48.0%** (YTD 63.7%, 3-mo 21.1%). The shares are up 48.0% over twelve months including dividends.
- **From 52-week high: -0.3%** (109.6% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 62**. An RSI of 62 is neutral.
- **Beta (1 yr): 1.02** (volatility 57%). Beta of 1.02 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=INFU · Page: https://foliofundamentals.com/stocks/infu

Not investment advice.